melagatran has been researched along with mci 9038 in 15 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (mci 9038) | Trials (mci 9038) | Recent Studies (post-2010) (mci 9038) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 1,087 | 83 | 349 |
| Protein | Taxonomy | melagatran (IC50) | mci 9038 (IC50) |
|---|---|---|---|
| Prothrombin | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Adang, AE; de Man, AP; Grootenhuis, PD; Kelder, J; Lucas, H; Meuleman, DG; Peters, CA; Rewinkel, JB; Smit, MJ; van Aelst, S; van Boeckel, CA; van Dinther, T; Visser, A; Vogel, GM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Cho, KH; Kim, A; Kim, TH; Lee, SH; Park, HD | 1 |
| Deinum, J; Elg, M; Gustafsson, D | 1 |
| Deinum, J; Nilsson, T; Sjöling-Ericksson, A | 1 |
| Hauptmann, J; Steinmetzer, T; Sturzebecher, J | 1 |
| Fleischer, K; Gulba, DC; Lankes, W | 1 |
| Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I | 1 |
| Fenyvesi, T; Harenberg, J; Joerg, I | 1 |
| Adams, TE; Everse, SJ; Mann, KG | 1 |
| Bauersachs, R; Brehme, S; Caspary, L; Creutzig, A; Harenberg, J; Hoffmann, U; Landgraf, H; Schellong, S | 1 |
| Craven, S; Dewar, L; Greinacher, A; Ofosu, FA; Sheppard, JA; Warkentin, TE | 1 |
| Kalb, ML; Kozek-Langenecker, SA; Potura, L; Scharbert, G | 1 |
5 review(s) available for melagatran and mci 9038
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Advances in the development of thrombin inhibitors.
Topics: Arginine; Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Hirudin Therapy; Hirudins; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2001 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
[Prevention and treatment of deep vein thrombosis with ximelagatran].
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy; Humans; Pipecolic Acids; Polysaccharides; Prodrugs; Sulfonamides; Thrombin; Venous Thrombosis | 2004 |
10 other study(ies) available for melagatran and mci 9038
| Article | Year |
|---|---|
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
Topics: Administration, Oral; Animals; Aorta; Biological Availability; Biological Transport, Active; Caco-2 Cells; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolytic Agents; Half-Life; Humans; In Vitro Techniques; Models, Molecular; Oligopeptides; Rats; Structure-Activity Relationship; Thrombin; Thrombosis | 2002 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
Topics: Amidines; Animals; Antithrombins; Dipeptides; Dogs; Fluoroacetates; Haplorhini; Humans; Prodrugs; Rabbits; Rats; Thrombin; Thrombosis | 2013 |
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
Topics: Antithrombins; Area Under Curve; Arginine; Azetidines; Benzylamines; Binding Sites; Dipeptides; Fluorescence; Glycine; Humans; Kinetics; Molecular Weight; Pipecolic Acids; Piperidines; Spectrometry, Fluorescence; Spectrophotometry; Sulfonamides; Thrombin | 1998 |
Monitoring of anticoagulant effects of direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation Tests; Drug Monitoring; Glycine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombin | 2002 |
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Synergism; Glycine; Hirudins; Humans; Phenprocoumon; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides | 2002 |
Predicting the pharmacology of thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Topics: Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Cattle; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Glycine; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Species Specificity; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2005 |
The effect of ex vivo anticoagulants on whole blood platelet aggregation.
Topics: Adenosine Diphosphate; Anticoagulants; Arachidonic Acid; Arginine; Azetidines; Benzylamines; Blood Platelets; Citric Acid; Collagen; Female; Heparin; Hirudins; Humans; Male; Peptide Fragments; Pipecolic Acids; Platelet Aggregation; Platelet Function Tests; Recombinant Proteins; Ristocetin; Sulfonamides; Time Factors | 2009 |